Fig. 6.

SO1989 did not exhibit obvious side effects on adipose and appetite in HFD mice in comparison with CDDO-Me. (a–b) HFD-mice treated with the vehicle, indicated doses of CDDO-Me or SO1989 for 15 days, the effect of CDDO-Me or SO1989 on body weight (a) and adipose weight (b) (n = 6). IAT:inguinal adipose tissue, EAT:epididymal adipose tissue，MAT:Mesenteric adipose tissue, PAT: perirenal adipose tissue. (c) The effect of CDDO-Me or SO1989 on food intake in HFD mice. For each mouse, average daily food intakes were calculated (n = 6). (d) The leptin levels in serum upon the CDDO-Me or SO1989 administration were detected by ELISA kit (n = 6). (e) The expression levels of leptin in EAT and IAT were analyzed by qRT-PCR (n = 6). (f) The mice were placed in metabolic cages and urine was collected. The levels of urine protein and CRE in serum were detected by commercial kit (n = 6). All statistical analysis is based on one-way ANOVA. ^⁎P < 0.05, ^⁎⁎P < 0.01, ^⁎⁎⁎P < 0.001. Data are presented as mean ± SEM.